






Control Arm

BEAT

Protocol Overview Study Design

- Primary Stage IVB, persistent or recurrent carcinoma of the cervix
- Measurable disease by RECIST v1.1
- ECOG-PS: 0-1
- No previous systemic chemotherapy for advanced or recurrent disease
- N=404 pt



Stratification Factors:

- Prior concurrent Cisplatin-Radio Therapy
- Histology: Squamous vs. adenocarcinoma
- Chemotherapy Backbone: Cisplatin vs Carboplatin

After amendment approval



A tumor specimen is mandatory at study entry.

This may be an archival biopsy or, in its absence, a tumor biopsy obtained within 3 months of randomization from a non-irradiated lesion.







